Expanded Access Study of Remdesivir to Treat COVID-19 Infection


Full Title

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID)


In this study, researchers are assessing the effectiveness of the investigational antiviral drug remdesivir to treat infections caused by the SARS-CoV2 virus, such as COVID-19. When tested in the laboratory and in some patients, remdesivir has been shown to fight against SARS-2-CoV and similar types of viruses. Researchers think that remdesivir may reduce the amount of time for recovery and the likelihood of spreading the illness. The treatment is given intravenously (by vein) for 10 days.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have serious COVID-19 infection that requires hospitalization and mechanical ventilation.
  • Patients may not have evidence of kidney failure or the failure of multiple organs.
  • This study is for patients age 18 and older. Younger patients age 12-17 may also participate if they weight at least 40 kg (about 88 lbs).

For more information about this study, please contact Dr. Susan Seo at 212-639-3151.